Top

The Journal of Headache and Pain

Published in:

Open Access 01-12-2018 | Review article

PACAP and its receptors in cranial arteries and mast cells

Authors: Inger Jansen-Olesen, Sara Hougaard Pedersen

Published in: The Journal of Headache and Pain | Issue 1/2018

Abstract

Background

In migraineurs pituitary adenylate cyclase activating peptide1–38 (PACAP1–38) is a potent migraine provoking substance and the accompanying long lasting flushing suggests degranulation of mast cells. Infusion of the closely related vasoactive intestinal peptide (VIP) either induces headache or flushing. This implicates the pituitary adenylate cyclase activating peptide type I receptor (PAC1) to be involved in the pathophysiology of PACAP1–38 provoked headaches. Here we review studies characterizing the effects of mainly PACAP but also of VIP on cerebral and meningeal arteries and mast cells.

Discussion

PACAP1–38, PACAP1–27 and VIP dilate cerebral and meningeal arteries from several species including man. In rat cerebral and meningeal arteries the dilation seems to be mediated preferably via vasoactive intestinal peptide receptor type 1 (VPAC1) receptors while, in human, middle meningeal artery dilation induced via vasoactive intestinal peptide receptor type 2 (VPAC2) receptors cannot be ruled out. PACAP1–38 is a strong degranulator of peritoneal and dural mast cells while PACAP1–27 and VIP only have weak effects. More detailed characterization studies suggest that mast cell degranulation is not mediated via the known receptors for PACAP1–38 but rather via a still unknown receptor coupled to phospholipase C.

Conclusion

It is suggested that PACAP1–38 might induce migraine via degranulation of dural mast cells via a yet unknown receptor.

Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I et al (2013) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 386(9995):743–800CrossRef

Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B (2012) The economic cost of brain disorders in Europe. Eur J Neurol 19(1):155–162CrossRefPubMed

Tfelt-Hansen P, Olesen J (2012) Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs 26(5):375–382CrossRefPubMed

Arimura A, Somogyvári-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C (1991) Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129(5):2787–2789CrossRefPubMed

Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M et al (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170(2):643–648CrossRefPubMed

Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52(2):269–324PubMed

Zagami AS, Edvinsson L, Goadsby PJ (2014) Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol 1(12):1036–1040CrossRefPubMedPubMedCentral

Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsányi J, Szabó N et al (2013) Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 33(13):1085–1095CrossRefPubMed

Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW et al (2012) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 32(2):140–149CrossRefPubMed

10.

Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2008) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132(1):16–25CrossRefPubMed

11.

Rahmann A, Wienecke T, Hansen J, Fahrenkrug J, Olesen J, Ashina M (2008) Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28(3):226–236CrossRefPubMed

12.

Sherwood NM, Krueckl SL, McRory JE (2000) The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 21(6):619–670PubMed

13.

Fahrenkrug J (2006) PACAP—A multifacetted neuropeptide. Chronobiol Int 23(1–2):53–61CrossRefPubMed

14.

Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O et al (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61(3):283–357CrossRefPubMed

15.

Hannibal J, Fahrenkrug J (1995) Expression of pituitary adenylate cyclase activating polypeptide (PACAP) gene by rat spermatogenic cells. Regul Pept 55(1):111–115CrossRefPubMed

16.

Chen Y, Samal B, Hamelink CR, Xiang CC, Chen Y, Chen M et al (2006) Neuroprotection by endogenous and exogenous PACAP following stroke. Regul Pept 137(1):4–19CrossRefPubMedPubMedCentral

17.

Vaudry D, Hamelink C, Damadzic R, Eskay RL, Gonzalez B, Eiden LE, Endogenous PACAP (2005) Acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult. Peptides 26(12):2518–2524CrossRefPubMedPubMedCentral

18.

Dickinson T, Fleetwood-Walker S, Mitchell R, Lutz E (1997) Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs. Neuropeptides 31(2):175–185CrossRefPubMed

19.

Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR et al (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50(2):265–270PubMed

20.

Edvinsson L, Elsås T, Suzuki N, Shimizu T, Jer-Fu Lee T (2001) Origin and co-localization of nitric oxide synthase, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microsc Res Tech 53(3):221–228CrossRefPubMed

21.

Mulder H, Uddman R, Moller K, Elsås T, Ekblad E, Alumets J et al (1995) Pituitary adenylate cyclase activating polypeptide is expressed in autonomic neurons. Regul Pept 59(1):121–128CrossRefPubMed

22.

Uddman R, Goadsby P, Jansen I, Edvinsson L (1993) PACAP, a VIP-like peptide: immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. J Cereb Blood Flow Metab 13(2):291–297CrossRefPubMed

23.

Dalsgaard T, Hannibal J, Fahrenkrug J, Larsen CR, Ottesen BVIP (2003) PACAP display different vasodilatory effects in rabbit coronary and cerebral arteries. Regul Pept 110(3):179–188CrossRefPubMed

24.

Fahrenkrug J, Hannibal J, Tams J, Georg B (2000) Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab 20(8):1205–1214CrossRefPubMed

25.

Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14(11):1289–1303CrossRefPubMed

26.

Jansen-Olesen I, Baun M, Amrutkar DV, Ramachandran R, Christophersen DV, Olesen J (2014) PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC 1 receptor. Neuropeptides 48(2):53–64CrossRefPubMed

27.

Mulder H, Uddman R, Moller K, Zhang Y-Z, Ekblad E, Alumets J et al (1994) Pituitary adenylate cyclase activating polypeptide expression in sensory neurons. Neuroscience 63(1):307–312CrossRefPubMed

28.

Tajti J, Uddman R, Möller S, Sundler F, Edvinsson L (1999) Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 76(2):176–183CrossRefPubMed

29.

Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L (2002) Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 22(2):112–116CrossRefPubMed

30.

Ciccarelli E, Svoboda M, De Neef P, Di Paolo E, Bollen A, Dubeaux C et al (1995) Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells. Eur J Pharmacol 288(3):259–267CrossRefPubMed

31.

Chan KY, Baun M, Vries RD, van den Bogaerdt AJ, Dirven CM, Danser AH et al (2011) Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia 31(2):181–189CrossRefPubMed

32.

Knutsson M, Edvinsson L (2002) Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport 13(4):507–509CrossRefPubMed

33.

Boni L, Ploug KB, Olesen J, Jansen-Olesen I, Gupta S (2009) The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. Cephalalgia 29(8):837–847CrossRefPubMed

34.

Baun M, Hay-Schmidt A, Edvinsson L, Olesen J, Jansen-Olesen I (2011) Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat. Eur J Pharmacol 670(1):186–194CrossRefPubMed

35.

Kelman L (2005) Migraine pain location: a tertiary care study of 1283 migraineurs. Headache 45(8):1038–1047CrossRefPubMed

36.

Ray BS, Wolff HG (1940) Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Arch Surg 41(4):813–856CrossRef

37.

Fricke B, Andres KH, Von Düring M (2001) Nerve fibers innervating the cranial and spinal meninges: morphology of nerve fiber terminals and their structural integration. Microsc Res Tech 53(2):96–105CrossRefPubMed

38.

Mayberg M, Langer RS, Zervas NT, Moskowitz MA (1981) Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headaches in man. Science 213(4504):228–230CrossRefPubMed

39.

Headache Classification Committee of the International Headache Society (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33(9):629–808CrossRef

40.

Iversen HK, Olesen J, Tfelt-Hansen P (1989) Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 38(1):17–24CrossRefPubMed

41.

Lassen L, Haderslev P, Jacobsen V, Iversen HK, Sperling B, Olesen JCGRP (2002) May play a causative role in migraine. Cephalalgia 22(1):54–61CrossRefPubMed

42.

Thomsen LL, Iversen HK, Brinck TA, Olesen J (1993) Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia 13(6):395–399CrossRefPubMed

43.

Wienecke T, Olesen J, Oturai PS, Ashina M (2008) Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain 139(1):106–116CrossRefPubMed

44.

Kruuse C, Thomsen LL, Birk S, Olesen J (2003) Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126(1):241–247CrossRefPubMed

45.

Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJ et al (2013) Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol 12(5):454–461CrossRefPubMed

46.

Jansen-Olesen I, Goadsby PJ, Uddman R, Edvinsson L (1994) Vasoactive intestinal peptide (VIP) like peptides in the cerebral circulation of the cat. J Auton Nerv Syst 49:97–103CrossRef

47.

Grände G, Nilsson E, Edvinsson L (2013) Comparison of responses to vasoactive drugs in human and rat cerebral arteries using myography and pressurized cerebral artery method. Cephalalgia 33(3):152–159CrossRefPubMed

48.

Jansen-Olesen I, Gulbenkian S, Engel U, Cunha e Sá M, Edvinsson L (2004) Peptidergic and non-peptidergic innervation and vasomotor responses of human lenticulostriate and posterior cerebral arteries. Peptides 25(12):2105–2114CrossRefPubMed

49.

Banks WA, Kastin AJ, Komaki G, Arimura A (1993) Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood–brain barrier. J Pharmacol Exp Ther 267(2):690–696PubMed

50.

Dogrukol-Ak D, Tore F, Tuncel N (2004) Passage of VIP/PACAP/secretin family across the blood–brain barrier: therapeutic effects. Curr Pharm Des 10(12):1325–1340CrossRefPubMed

51.

Barzo P, Bari F, Doczi T, Jancso G, Bodosi M (1993) Significance of the rate of systemic change in blood pressure on the short-term autoregulatory response in normotensive and spontaneously hypertensive rats. Neurosurgery 32(4):611–618CrossRefPubMed

52.

Gupta S, Bhatt D, Boni L, Olesen J (2010) Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. Cephalalgia 30(1):27–36CrossRefPubMed

53.

Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J et al (2007) The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 140(3):185–191CrossRefPubMed

54.

Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132(Pt 1):16–25CrossRefPubMed

55.

Syed AU, Koide M, Braas KM, May V, Wellman GC (2012) Pituitary Adenylate Cyclase-activating polypeptide (PACAP) potently dilates middle Meningeal arteries: implications for migraine. J Mol Neurosci 48(3):574–583CrossRefPubMedPubMedCentral

56.

Syed AU, Koide M, May V, Wellman GC. PACAP regulation of vascular tone: differential mechanism among vascular beds. In: Reglodi D, Tamas A, editors. Pituitary Adenylate Cyclase activating polypeptide — PACAP. Curr Top Neurotox. 2016 11:617–630. Springer International Publishing

57.

Grände G, Labruijere S, Haanes KA, MaassenVanDenBrink A, Edvinsson L (2014) Comparison of the vasodilator responses of isolated human and rat middle meningeal arteries to migraine related compounds. J Headache Pain 15(1):22CrossRefPubMedPubMedCentral

58.

Akerman S, Goadsby PJ (2015) Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med 7(308):308ra157CrossRefPubMed

59.

Bhatt DK, Gupta S, Olesen J, Jansen-Olesen I (2014) PACAP-38 infusion causes sustained vasodilation of the middle meningeal artery in the rat: possible involvement of mast cells. Cephalalgia 34(11):877–886CrossRefPubMed

60.

Gri G, Frossi B, D’Inca F, Danelli L, Betto E, Mion F, et al (2012) Mast cell: an emerging partner in immune interaction. Front Immunol 3:120

61.

Brown JM, Wilson TM, Metcalfe DD (2008) The mast cell and allergic diseases: role in pathogenesis and implications for therapy. Clin Exp Allergy 38(1):4–18PubMed

62.

Nakano T, Sonoda T, Hayashi C, Yamatodani A, Kanayama Y, Yamamura T et al (1985) Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J Exp Med 162(3):1025–1043CrossRefPubMed

63.

Okayama Y, Kawakami T (2006) Development, migration, and survival of mast cells. Immunol Res 34(2):97–115CrossRefPubMedPubMedCentral

64.

Warbrick EV, Taylor AM, Botchkarev VA, Coleman JW (1995) Rat connective tissue-type mast cells express MHC class II: up-regulation by IFN-gamma. Cell Immunol 163(2):222–228CrossRefPubMed

65.

Zhang D, Spielmann A, Wang L, Ding G, Huang F, Gu Q et al (2012) Mast-cell degranulation induced by physical stimuli involves the activation of transient-receptor-potential channel TRPV2. Physiol Res 61(1):113PubMed

66.

Gazerani P, Pourpak Z, Ahmadiani A, Hemmati A, Kazemnejad AA (2003) Correlation between migraine, histamine and immunoglobulin E. Scand J Immunol 57(3):286–290CrossRefPubMed

67.

Heatley R, Denburg J, Bayer N, Bienenstock J (1982) Increased plasma histamine levels in migraine patients. Clinical & Experimental. Allergy 12(2):145–149

68.

Kemper R, Meijler W, Korf J, Ter Horst G (2001) Migraine and function of the immune system: a meta-analysis of clinical literature published between 1966 and 1999. Cephalalgia 21(5):549–557CrossRefPubMed

69.

Mansfield LE, Vaughan T, Waller SF, Haverly RW, Ting S (1985) Food allergy and adult migraine: double-blind and mediator confirmation of an allergic etiology. Ann Allergy 55(2):126–129PubMed

70.

Peng Y-H, Chen K-F, Kao C-H, Chen H-J, Hsia T-C, Chen C-H et al (2016) Risk of migraine in patients with asthma: a nationwide cohort study. Medicine 95:9

71.

Wilson C, Kirker J, Warnes H, O'Malley M (1980) The clinical features of migraine as a manifestation of allergic disease. Postgrad Med J 56(659):617–621CrossRefPubMedPubMedCentral

72.

Ku M, Silverman B, Prifti N, Ying W, Persaud Y, Schneider A (2006) Prevalence of migraine headaches in patients with allergic rhinitis. Ann Allergy Asthma Immunol 97(2):226–230CrossRefPubMed

73.

Lassen LH, Thomsen LL, Olesen J (1995) Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport 6(11):1475–1479CrossRefPubMed

74.

Anthony M, Lord G, Lance J (1978) Controlled trials of cimetidine in migraine and cluster headache. Headache 18(5):261–264CrossRefPubMed

75.

Millan-Guerrero RO, Isais-Millan R, Benjamin TH, Tene CE (2006) Nalpha-methyl histamine safety and efficacy in migraine prophylaxis: phase III study. The Canadian journal of neurological sciences. J Can Sci Neurol 33(2):195–199CrossRef

76.

Alstadhaug KB (2014) Histamine in migraine and brain. Headache 54(2):246–259CrossRefPubMed

77.

Strassman A, Raymond S, Burstein R (1996) Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384(6609):560CrossRefPubMed

78.

Zhang X-C, Strassman AM, Burstein R, Levy D (2007) Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther 322(2):806–812CrossRefPubMed

79.

Wienecke T, Olesen J, Ashina M (2011) Discrepancy between strong cephalic arterial dilatation and mild headache caused by prostaglandin D2 (PGD2). Cephalalgia 31(1):65–76CrossRefPubMed

80.

Pedersen SH, Ramachandran R, Amrutkar DV, Petersen S, Olesen J, Jansen-Olesen I (2015) Mechanisms of glyceryl trinitrate provoked mast cell degranulation. Cephalalgia 35(14):1287–1297CrossRefPubMed

81.

Reuter U, Bolay H, Jansen-Olesen I, Chiarugi A, del Rio MS, Letourneau R et al (2001) Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 124(12):2490–2502CrossRefPubMed

82.

Baun M, Pedersen MHF, Olesen J, Jansen-Olesen I (2012) Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. Cephalalgia 32(4):337–345CrossRefPubMed

83.

Levy D (2009) Migraine pain, meningeal inflammation, and mast cells. Curr Pain Headache Rep 13(3):237–240CrossRefPubMed

84.

Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM (2007) Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 130(1):166–176CrossRefPubMedPubMedCentral

85.

Levy D, Burstein R, Strassman AM (2006) Mast cell involvement in the pathophysiology of migraine headache: a hypothesis. Headache 46:s1CrossRef

86.

Ødum L, Petersen L, Skov P, Ebskov L (1998) Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res 47(12):488–492CrossRefPubMed

87.

Schmidt-Choudhury A, Furuta GT, Galli SJ, Schmidt WE, Wershil BK (1999) Mast cells contribute to PACAP-induced dermal oedema in mice. Regul Pept 82(1):65–69CrossRefPubMed

88.

Li M, Maderdrut JL, Lertora JJ, Batuman V (2007) Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study. Peptides 28(9):1891–1895CrossRefPubMed

89.

Saghy E, Payrits M, Helyes Z, Reglodi D, Banki E, Toth G et al (2015) Stimulatory effect of pituitary adenylate cyclase-activating polypeptide 6–38, M65 and vasoactive intestinal polypeptide 6–28 on trigeminal sensory neurons. Neuroscience 308:144–156CrossRefPubMed

90.

Erdling A, Sheykhzade M, Maddahi A, Bari F, Edvinsson LVIP (2013) PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium. Neuropeptides 47(2):85–92CrossRefPubMed

91.

Sismanopoulos N, Delivanis D-A, Alysandratos K-D, Angelidou A, Therianou A, Kalogeromitros D et al (2012) Mast cells in allergic and inflammatory diseases. Curr Pharm Des 18(16):2261–2277CrossRefPubMed

Title: PACAP and its receptors in cranial arteries and mast cells
Authors: Inger Jansen-Olesen
Sara Hougaard Pedersen
Publication date: 01-12-2018
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2018
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-017-0822-2

At a glance: The STEP trials

Springer Medicine

PACAP and its receptors in cranial arteries and mast cells

Abstract

Background

Discussion

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Discussion

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Poor medical care for people with migraine in Europe – evidence from the Eurolight study

Headache attributed to aeroplane travel: the first multicentric survey in a paediatric population affected by primary headaches

Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?

Correction to: Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial

The association between migraine and physical exercise

Altered muscle activity during rest and during mental or physical activity is not a trait symptom of migraine - a neck muscle EMG study